Read by QxMD icon Read

Diabetes Technology & Therapeutics

Amerta Ghosh, Anoop Misra
No abstract text is available yet for this article.
October 18, 2016: Diabetes Technology & Therapeutics
Leonor García Maset, Lidia Blasco González, Gonzalo Llop Furquet, Francisco Montes Suay, Roberto Hernández Marco
BACKGROUND: Time series analysis provides information on blood glucose dynamics that is unattainable with conventional glycemic variability (GV) indices. To date, no studies have been published on these parameters in pediatric patients with type 1 diabetes. Our aim is to evaluate the relationship between time series analysis and conventional GV indices, and glycosylated hemoglobin (HbA1c) levels. METHODS: This is a transversal study of 41 children and adolescents with type 1 diabetes...
October 11, 2016: Diabetes Technology & Therapeutics
Christopher G Parkin, Anita Homberg, Rolf Hinzmann
International experts in the field of diabetes and diabetes technology met in Madrid, Spain, for the 9th Annual Symposium on Self-Monitoring of Blood Glucose. The goal of these meetings is to establish a global network of experts, thus facilitating new collaborations and research projects to improve the lives of people with diabetes. The 2016 meeting comprised a comprehensive scientific program, parallel interactive workshops, and two keynote lectures.
October 6, 2016: Diabetes Technology & Therapeutics
James Weimer, Sanjian Chen, Amy Peleckis, Michael R Rickels, Insup Lee
BACKGROUND: Fully automated artificial pancreas systems require meal detectors to supplement blood glucose level regulation, where false meal detections can cause unnecessary insulin delivery with potentially fatal consequences, and missed detections may cause the patient to experience extreme hyperglycemia. Most existing meal detectors monitor various measures of glucose rate-of-change to detect meals where varying physiology and meal content complicate balancing detector sensitivity versus specificity...
October 5, 2016: Diabetes Technology & Therapeutics
Anette-G Ziegler, Florian Haupt, Marlon Scholz, Katharina Weininger, Susanne Wittich, Stephanie Löbner, Claudia Matzke, Cigdem Gezginci, Stephanie Riethausen, Andreas Beyerlein, Stephanie Zillmer, Marie Amoroso, Rebecca Coles, Michael Powell, Jadwiga Furmaniak, Bernard Rees Smith, Christiane Winkler, Ezio Bonifacio, Peter Achenbach
BACKGROUND: Testing for beta cell autoantibodies is used for wide-scale identification of early stages of type 1 diabetes. This requires suitable screening assays. We aimed to establish screening that utilized a first step assay (3 Screen) able to detect autoantibodies to the target antigens glutamic acid decarboxylase-65 (GAD), insulinoma-associated antigen 2 (IA-2), and zinc transporter 8 (ZnT8) to identify children positive for multiple beta cell autoantibodies. METHODS: An ELISA format was used where plates were coated with a mixture of recombinant GAD, IA-2, and ZnT8325W/R-dimer molecules...
August 23, 2016: Diabetes Technology & Therapeutics
Robert R Henry, Eric J Klein, Jenny Han, Nayyar Iqbal
BACKGROUND: Long-term treatment is necessary to slow the progression of type 2 diabetes (T2D). Here, we examined the safety and efficacy of 6 years of treatment with exenatide once weekly (QW) among patients with T2D in the DURATION-1 trial. METHODS: The study enrolled patients aged ≥16 years with T2D treated primarily with metformin and sulfonylureas. Following 30 weeks of randomized treatment with exenatide QW 2 mg or exenatide twice daily 10 μg, patients entered an uncontrolled, open-label, open-ended study phase in which all patients received exenatide QW 2 mg...
August 15, 2016: Diabetes Technology & Therapeutics
Katharine D Barnard, Amanda Blatch-Jones
No abstract text is available yet for this article.
October 2016: Diabetes Technology & Therapeutics
Filiz Demircik, David Klonoff, Petra B Musholt, Sanja Ramljak, Andreas Pfützner
BACKGROUND: Devices employing electrochemistry-based correction algorithms (EBCAs) are optimized for patient use and require special handling procedures when tested in the laboratory. This study investigated the impact of sample handling on the results of an accuracy and hematocrit interference test performed with BG*Star, iBG*Star; OneTouch Verio Pro and Accu-Chek Aviva versus YSI Stat 2300. METHODS: Venous heparinized whole blood was manipulated to contain three different blood glucose concentrations (64-74, 147-163, and 313-335 mg/dL) and three different hematocrit levels (30%, 45%, and 60%)...
October 2016: Diabetes Technology & Therapeutics
Enrique Campos-Náñez, Boris P Kovatchev
No abstract text is available yet for this article.
October 2016: Diabetes Technology & Therapeutics
William H Polonsky, Danielle Hessler, Jennifer E Layne, Howard Zisser
BACKGROUND: Few recent studies have examined the impact of continuous subcutaneous insulin infusion systems on patient-reported quality of life (QOL). We explored QOL changes resulting from treatment with the Omnipod(®) Insulin Management System (Insulet Corp., Billerica, MA). METHODS: One thousand two hundred forty-five adults (>18 years) with type 1 diabetes and current Omnipod users completed an online questionnaire examining perceived changes in QOL and glycemic control since Omnipod initiation...
October 2016: Diabetes Technology & Therapeutics
Alex Zhong, Pratik Choudhary, Chantal McMahon, Pratik Agrawal, John B Welsh, Toni L Cordero, Francine R Kaufman
BACKGROUND: Automated insulin management features of the MiniMed(®) 640G sensor-augmented pump system include suspension in response to predicted low sensor glucose (SG) values ("suspend before low"), suspension in response to existing low SG values ("suspend on low"), and automatic restarting of basal insulin delivery upon SG recovery. The effectiveness of these features was evaluated using CareLink(®) software data. METHODS: Anonymized data from MiniMed 640G system users (n = 4818), MiniMed 530G system users (n = 39,219), and MiniMed Paradigm(®) Veo™ system users (n = 43,193) who voluntarily uploaded pump and sensor data were retrospectively analyzed...
October 2016: Diabetes Technology & Therapeutics
Harpreet S Bajaj, Karri Venn, Chenglin Ye, Ronnie Aronson
BACKGROUND: Basal insulin titration in the real world is often unsuccessful. LTHome, a web tool, applies a rules engine-based algorithm providing insulin titration advice directly to the patient. METHODS: This pilot, randomized trial evaluates basal insulin glargine titration by LTHome compared to enhanced usual therapy ([EUT]-diabetes education program) over 12 weeks. Important inclusion criteria: 18-75 years, type 2 diabetes, computer literacy, and HbA1c >7...
October 2016: Diabetes Technology & Therapeutics
Jia Zhu, Peter Kahn, Janine Knudsen, Sanjeev N Mehta, Robert A Gabbay
BACKGROUND: The cost of diabetes care accounts for a significant proportion of healthcare expenditures. Cost models based on updated incident complication rates and associated costs are needed to improve financial planning and quality assessment across the U.S. healthcare system. We developed a cost model using published data to estimate the direct medical costs of incident diabetes-related complications in a U.S. population of adults. MATERIALS AND METHODS: A systematic literature review of MEDLINE, EMBASE, and TRIP databases was conducted on studies reporting the incidence and/or cost of diabetes-related complications (cardiovascular disease, neuropathy, nephropathy, ophthalmological disease, and acute metabolic events)...
October 2016: Diabetes Technology & Therapeutics
Ping Hu, Xiang-Hai Zhou, Xin Wen, Linong Ji
BACKGROUND: Risk factors related to renal function decline in type 2 diabetes mellitus (T2DM) remain uncertain. This study aimed to investigate risk factors in relation to renal function decline in patients with T2DM and in a subgroup of patients with normoalbuminuria. METHODS: This study was a retrospective cohort study, which included 451 patients with T2DM aged 63 ± 14 years admitted to a tertiary hospital in Beijing, China, between April and December 2010 and followed up for 6-60 months...
October 2016: Diabetes Technology & Therapeutics
Joni S Williams, Rebekah J Walker, Brittany L Smalls, Rachel Hill, Leonard E Egede
BACKGROUND: The Affordable Care Act places a newfound emphasis on patient-centered medical home and patient-centered care (PCC). The purpose of this study was to evaluate the relationship between PCC, diabetes self-care, glycemic control, and quality of life (QOL) in a sample of adults with type 2 diabetes. METHODS: Six hundred fifteen patients were recruited from two adult primary care clinics in the southeastern United States. Primary outcome variables were self-care behaviors (medication adherence, diet, exercise, blood sugar testing, and foot care), glycemic control, and QOL (physical component summary [PCS] score and mental component summary [MCS] score of SF12)...
October 2016: Diabetes Technology & Therapeutics
Mark R Burge, R Philip Eaton, David S Schade
The coronary artery calcium (CAC) scan has recently emerged as a reproducible noninvasive test to detect asymptomatic atherosclerotic coronary artery disease. It has several advantages over the traditional cardiac stress testing modalities, including lower cost, greater sensitivity for nonobstructing coronary artery lesions, and excellent prognostic value when combined with the Framingham risk parameters. Its chief disadvantage is that it does not identify obstructing coronary artery lesions or noncalcified coronary artery plaque...
September 2016: Diabetes Technology & Therapeutics
Dorothee Deiss, Peter Adolfsson, Marije Alkemade-van Zomeren, Geremia B Bolli, Guillaume Charpentier, Claudio Cobelli, Thomas Danne, Angela Girelli, Heiko Mueller, Carol A Verderese, Eric Renard
Insulin pump users worldwide depend on insulin infusion sets (IISs) for predictable delivery of insulin to the subcutaneous tissue. Yet emerging data indicates that IISs are associated with many pump-related adverse events and may contribute to potentially life-threatening problem of unexplained hyperglycemia. The relative scarcity of published research on IISs to date, the heterogeneity of regional IIS practices, and the increasing demand for international standards guiding their use prompted convening of a panel of diabetologists and diabetes nurse educators last February, in Milan, Italy, to discuss a framework for optimizing IIS practice in Europe...
September 2016: Diabetes Technology & Therapeutics
Mary B Abraham, Raymond Davey, Michael J O'Grady, Trang T Ly, Nirubasini Paramalingam, Paul A Fournier, Anirban Roy, Benyamin Grosman, Natalie Kurtz, Janice M Fairchild, Bruce R King, Geoffrey R Ambler, Fergus Cameron, Timothy W Jones, Elizabeth A Davis
BACKGROUND: Sensor-augmented pump therapy (SAPT) with a predictive algorithm to suspend insulin delivery has the potential to reduce hypoglycemia, a known obstacle in improving physical activity in patients with type 1 diabetes. The predictive low glucose management (PLGM) system employs a predictive algorithm that suspends basal insulin when hypoglycemia is predicted. The aim of this study was to determine the efficacy of this algorithm in the prevention of exercise-induced hypoglycemia under in-clinic conditions...
September 2016: Diabetes Technology & Therapeutics
Asma Deeb, Nabras Al Qahtani, Salima Attia, Hana Al Suwaidi, Nico Nagelkerke
BACKGROUND: Ramadan fasting by patients with type 1 diabetes might predispose them to hypoglycemia. There are no data on the optimal way of adjusting basal insulin during fasting. We aim at studying whether reducing basal insulin during Ramadan reduces the frequency of symptomatic hypoglycemia. METHODS: We enrolled children and adolescents with type 1 diabetes who intended to fast during Ramadan. Logbooks were given to subjects to mark days fasted, symptomatic hypoglycemia, and dose of basal insulin on all days of Ramadan...
September 2016: Diabetes Technology & Therapeutics
Efrat Kochba, Yotam Levin, Itamar Raz, Avivit Cahn
BACKGROUND: Currently available short-acting insulin analogs have slower absorption compared with endogenous insulin occasionally resulting in immediate postprandial hyperglycemia. Intradermal (ID) injection facilitates faster drug absorption and may result in improved insulin pharmacokinetics. METHODS: Seventeen patients with type 2 diabetes were included in this single-center, pilot, open-label crossover study. Patients received 0.2 U/kg Insulin aspart ID injections using a MicronJet (MJ) needle and subcutaneous (SC) injections, using a conventional needle in a crossover design...
September 2016: Diabetes Technology & Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"